Ancer Lung News Today

Microbial diversity affects whether a tumor grows, leads to inflammation, develops immune escape mechanisms, or develops therapeutic resistance, said an internal medicine specialist.

The guidance also recommends counseling to help patients and providers who are struggling with psychological or moral distress from ongoing shortages.

A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.

"We are seeing some truly surprising response rates and progression-free survival data," says chairman of Unicancer and general director of the Léon Bérard Center in France.

The next-generation tyrosine kinase inhibitor provides a new treatment option for patients with this difficult-to-treat form of lung cancer.

Stop-gain mutations interfere with the function of tumor suppressors, making it easier for cancer to take hold.

Marcy Duncan hadnt fully healed from her surgery for stage I breast cancer. She expected to discuss radiation and other next treatment steps. But her doctor raised a more serious concern.

New data indicate that tertiary lymphoid structures could predict which patients with advanced non-small cell lung cancer will benefit most from immunotherapy.

Researchers have identified biomarkers, alongside clinical risk factors, that may provide better cancer risk assessment and identify individuals who should be screened.

Unlike previous research, a recent study examines exposure to fine particulate matter pollution at home and at the workplace.